Abstract | OBJECTIVE: METHOD: A decision tree model for the treatment of bone pain due to metastases was adapted to the Spanish context. The model represents the standard treatment patterns in Spain for the study population. The time-course of the model is 4 months and it computes an estimate for the cost of pain control per patient. The effectiveness data for the model derive from a randomised trial. The current treatment patterns have been established according to the consensus opinions of a group of medical experts. RESULTS: The cost of pain control per patient is euro 12,515.39 for conventional therapy and euro 5,595.52 for samarium-153 ( Quadramet) therapy. The incremental cost-effectiveness analysis shows that samarium-153 ( Quadramet) is a dominant therapy. It presents lower costs and higher efficacy than the conventional strategy. The sensitivity analyses showed these results to be robust. CONCLUSION:
|
Authors | María Velasco Latrás, Luis Carreras Coderch, Fernando Antoñanzas Villar, Juan Coya Viña, José Martín Comín, Francisco Martínez Carderón, José Nieto Martín-Bejarano, Alberto Sáenz Cusí, Gala Serrano Bermúdez, Amaya Echevarría Icaza |
Journal | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
(Clin Transl Oncol)
Vol. 7
Issue 5
Pg. 198-204
(Jun 2005)
ISSN: 1699-048X [Print] Italy |
Vernacular Title | Análisis coste-efectividad de samario-153 (Quadramet) en el tratamiento del dolor en pacientes con cáncer de próstata y metástasis óseas. |
PMID | 15960931
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Analgesics, Non-Narcotic
- Organometallic Compounds
- Organophosphorus Compounds
- Radioisotopes
- Samarium
- samarium Sm-153 lexidronam
|
Topics |
- Adenocarcinoma
(drug therapy, economics, secondary)
- Analgesics, Non-Narcotic
(economics, therapeutic use)
- Bone Neoplasms
(drug therapy, economics, secondary)
- Cost-Benefit Analysis
- Drug Costs
- Humans
- Male
- Models, Economic
- Organometallic Compounds
(economics, therapeutic use)
- Organophosphorus Compounds
(economics, therapeutic use)
- Pain Measurement
(methods)
- Prostatic Neoplasms
(drug therapy, economics, pathology)
- Radioisotopes
(economics)
- Samarium
(economics)
- Treatment Outcome
|